look forward launch mirataz reiter neutral
clinical-stag
develop therapi pet compani
product pipelin includ small molecul
biolog rang indic dog
cat hors
requir disclosur end report
view current cl king meet event calendar coverag univers
kindr bioscienc went expect view
import part stori mirataz launch
compani promis product receiv approv mirataz
observ transit commerci stori mirataz might
success launch look reiter neutral rate
mirataz mirataz treatment inappet lack appetit cat
approv friday may drug label acut could
use label extens chronic case market huge three
million cat treat inappet annual accord kindr
suspect half cat suffer chronic inappet
remind mirataz topic formul absorb transderm
compani price drug per tube tube two week
worth daili dose
mirataz time kindr salesforc distributor partner begin take
order mirataz within next two week product packag
final fda-approv label updat begin ship suspect
within next two three month ultim drug need
ship distributor distributor need reorder
kindr recogn revenu model first mirataz revenu
number kindr post loss vs estim loss
loss last year vs estim
last year
zimeta oral/iv three week ago kindr receiv respons fda
zimeta iv fever hors fda conduct preapprov
inspect pai zimeta iv contract manufactur juli assum
posit inspect report juli chemistri manufactur control
technic section would take quarter complet would
take day approv receiv full new anim drug
applic nada approv zimeta oral complet unaffect zimeta
model lower revenu estim
due slightli slower
launch zimeta mirataz initi revenu
model respect ep vs
previous introduc ep
forecast
atop dermat zoeti annual run
rate project peak sale clear
approv compound atop dermat could blockbust potenti
kindr excit candid target regeneron
nr compound human function ident il-
apoquel cytopoint
commit fundrais
page
